PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 187 filers reported holding PDL BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is 2.92 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $37,000 | +12.1% | 13,082 | +3.0% | 0.00% | – |
Q3 2018 | $33,000 | -19.5% | 12,704 | -27.3% | 0.00% | – |
Q2 2018 | $41,000 | -50.0% | 17,477 | -37.6% | 0.00% | -100.0% |
Q1 2018 | $82,000 | -5.7% | 28,023 | -12.2% | 0.00% | 0.0% |
Q4 2017 | $87,000 | -37.4% | 31,911 | -22.2% | 0.00% | -50.0% |
Q3 2017 | $139,000 | +36.3% | 41,028 | -0.2% | 0.00% | +100.0% |
Q2 2017 | $102,000 | -1.9% | 41,122 | -10.5% | 0.00% | -50.0% |
Q1 2017 | $104,000 | +7.2% | 45,966 | +0.2% | 0.00% | 0.0% |
Q4 2016 | $97,000 | -25.4% | 45,862 | +18.6% | 0.00% | 0.0% |
Q3 2016 | $130,000 | +17.1% | 38,668 | +9.5% | 0.00% | 0.0% |
Q2 2016 | $111,000 | -55.1% | 35,311 | -52.3% | 0.00% | -66.7% |
Q1 2016 | $247,000 | -5.0% | 74,099 | +1.0% | 0.01% | 0.0% |
Q4 2015 | $260,000 | -34.2% | 73,368 | -6.5% | 0.01% | -45.5% |
Q3 2015 | $395,000 | -14.9% | 78,441 | +8.7% | 0.01% | -15.4% |
Q2 2015 | $464,000 | +176.2% | 72,185 | +202.0% | 0.01% | +160.0% |
Q1 2015 | $168,000 | – | 23,903 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |